BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18295867)

  • 1. Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination.
    Perry K; Wong L; Liu V; Park I; Zhang Q; Rejen V; Huang X; Smith ND; Jovanovic B; Lonning S; Teicher BA; Lee C
    Urology; 2008 Jul; 72(1):225-9. PubMed ID: 18295867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive cytolytic T cells for treatment of established mouse Renca tumors.
    Qin W; Tian F; Wang F; Song B; Wang H; Zhang Q; Jovanovic B; Liang L; Guo Y; Smith N; Lee C
    Urology; 2008 Oct; 72(4):943-7. PubMed ID: 18723212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of expression of transforming growth factor-beta type II receptor is associated with an aggressive growth pattern in a murine renal carcinoma cell line, Renca.
    Kundu SD; Kim IY; Zelner D; Janulis L; Goodwin S; Engel JD; Lee C
    J Urol; 1998 Nov; 160(5):1883-8. PubMed ID: 9783979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
    Kominsky SL; Doucet M; Brady K; Weber KL
    J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
    Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
    Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
    Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
    Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression.
    Maluccio M; Sharma V; Lagman M; Vyas S; Yang H; Li B; Suthanthiran M
    Transplantation; 2003 Aug; 76(3):597-602. PubMed ID: 12923450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
    Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
    J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of transfection of sense- and antisense-TGF beta 1 gene on human pulmonary giant cell carcinoma cell proliferation].
    Yang H; Lu Y; Shen H
    Zhonghua Zhong Liu Za Zhi; 1997 Mar; 19(2):89-92. PubMed ID: 10743067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
    Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
    Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells.
    Park JA; Wang E; Kurt RA; Schluter SF; Hersh EM; Akporiaye ET
    Cancer Gene Ther; 1997; 4(1):42-50. PubMed ID: 9012450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential.
    Miyake H; Hara I; Yoshimura K; Eto H; Arakawa S; Wada S; Chihara K; Kamidono S
    Cancer Res; 1996 May; 56(10):2440-5. PubMed ID: 8625325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
    Ashley DM; Kong FM; Bigner DD; Hale LP
    Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice.
    Tian F; Wang L; Qin W; Wang F; Song B; Li Y; Wen W; Zhang Z; Zhu K; Zhang Q; Lee C; Zhong W; Guo Y; Wang H
    Cancer Lett; 2008 Nov; 271(2):333-41. PubMed ID: 18675506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.
    Bandyopadhyay A; Zhu Y; Cibull ML; Bao L; Chen C; Sun L
    Cancer Res; 1999 Oct; 59(19):5041-6. PubMed ID: 10519421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
    Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
    Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
    Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor beta 1: lack of in vivo antitumor activity on A549 and Wehi 3BD+ tumors.
    Robinson SP; Rose WC
    Anticancer Res; 1992; 12(1):73-9. PubMed ID: 1567184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.